Calidi Biotherapeutics Plans $100M+ Public Offering to Fuel Pipeline
Event summary
- Calidi Biotherapeutics plans underwritten public offering of common stock and pre-funded warrants, with underwriters having 45-day option to purchase additional 15% of shares.
- Proceeds will be used for working capital and general corporate purposes.
- Offering made pursuant to effective Form S-3 registration statement (File No. 333-284229).
- Ladenburg Thalmann & Co. Inc. serves as sole book-running manager.
The big picture
This offering represents Calidi's latest move to secure non-dilutive capital for its targeted genetic medicine pipeline, particularly its Redtail platform focused on metastatic cancer treatments. The move comes amid heightened competition in oncology virotherapies and follows a year of strategic positioning in the precision medicine space. Success here would provide critical runway for CLD-401's IND-enabling studies and platform expansion.
What we're watching
- Funding Execution
- Whether Calidi can successfully close the offering at the proposed scale and terms.
- Pipeline Progress
- How proceeds will accelerate development of CLD-401 and other Redtail platform candidates.
- Market Conditions
- Impact of broader biotech sector volatility on investor appetite for Calidi's offering.
Related topics